Following a limited submission
AWMSG advice |
|||
| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED JULY 2017. Refer to TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | adalimumab (Humira®) | ||
| Formulation | 40 mg / 0.8 ml solution for injection | ||
| Reference number | 2571 | ||
| Indication | Treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies |
||
| Company | AbbVie Ltd | ||
| BNF chapter | Skin | ||
| Submission type | Limited | ||
| Status | Superseded | ||
| Advice number | 3615 | ||
| NMG meeting date | 07/10/2015 | ||
| AWMSG meeting date | 11/11/2015 | ||
| Ratification by Welsh Government | 09/12/2015 | ||
| Date of issue | 10/12/2015 | ||
| NICE guidance | |||